VIAMI：Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial).
Department of Cardiology， VU University Medical Center， De Boelelaan 1117， 1081 HV Amsterdam， The Netherlands. rb.vanloon@vumc.nl.
BACKGROUND: Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI)， to date most patients， even in developed countries， are reperfused with intravenous thrombolysis or do not receive a reperfusion therapy at all. In the post-lysis period these patients are at high risk for recurrent ischemic events. Early identification of these patients is mandatory as this subgroup could possibly benefit from an angioplasty of the infarct-related artery.Since viability seems to be related to ischemic adverse events， we initiated a clinical trial to investigate the benefits of PCI with stenting of the infarct-related artery in patients with viability detected early after acute myocardial infarction.
METHODS: The VIAMI-study is designed as a prospective， multicenter， randomized， controlled clinical trial. Patients who are hospitalized with an acute myocardial infarction and who did not have primary or rescue PCI， undergo viability testing by low-dose dobutamine echocardiography (LDDE) within 3 days of admission. Consequently， patients with demonstrated viability are randomized to an invasive or conservative strategy. In the invasive strategy patients undergo coronary angiography with the intention to perform PCI with stenting of the infarct-related coronary artery and concomitant use of abciximab. In the conservative group an ischemia-guided approach is adopted (standard optimal care).The primary end point is the composite of death from any cause， reinfarction and unstable angina during a follow-up period of three years.
CONCLUSION: The primary objective of the VIAMI-trial is to demonstrate that angioplasty of the infarct-related coronary artery with stenting and concomitant use of abciximab results in a clinically important risk reduction of future cardiac events in patients with viability in the infarct-area， detected early after myocardial infarction.